Abstract
Background: Medical therapy for refractory angina is limited and the prognosis is poor. Experimental data suggest that the use of extracorporeal shockwave myocardial revascularization (ESMR) can contribute to angiogenesis and improve symptoms of angina and left ventricular (LV) function. The objective of this study was to examine the effects of ESMR on clinical symptoms as well as LV function as assessed by cardiac MRI in patients with refractory angina.
Methods: Patients with Canadian Cardiovascular Society (CCS) class III-IV angina despite medical therapy and ischemia documented on thallium or echo-dobutamine were eligible for the study. ESMR therapy was applied with a commercially available cardiac shockwave generator system under echocardiographic guidance. LV function was assessed before and 6 months after therapy by cardiac MRI.
Results: Twenty patients (four women, 16 men; mean age 64 years, range 45-83) were included in the study. The CCS class after treatment improved in all patients (16 patients angina pectoris CCS from III to II and four patients from IV to III). The use of sublingual nitroglycerin was significantly reduced as well. There was a significant improvement in LV ejection fraction as assessed by blinded MRI following therapy in the overall population (51 vs. 59%, P<0.05).
Conclusion: This study demonstrates the potential efficacy of ESMR for the treatment of refractory angina pectoris. The patients showed both a significant clinical response as well as improved LV ejection fraction on serial MRI imaging. Larger studies are needed to adequately define the clinical utility of this novel therapy. Previous experimental studies have suggested a beneficial effect of extracorporeal shock wave therapy (ESWT) in patients with ischemic heart failure. Twenty-four patients with ischemic heart failure and left ventricular ejection fraction (LVEF) <40% received ESWT in addition to their stable treatment. ESWT was performed in 9 sessions with 100 shocks per spot in viable segments detected by dobutamine stress echocardiography. Patients were evaluated at baseline and at 3 and 6 months after ESWT. Tc-99m MIBI single photon emission computed tomography was performed on inclusion and at 6 months. ESWT significantly decreased New York Heart Association class from 2.2±0.8 to 1.7±0.7 at 3 months (P<.01) and 6 months after ESWT (1.7±0.7). Six-minute walk test improved from 414±141 to 509±141 and 538±116 (P<.01) at 3 and 6 months, respectively. A steady decrease of Canadian Cardiovascular Society angina class from 2.6±0.7 to 2.1±0.8 and 1.9±0.7 (P<.01) at 3 and 6 months, respectively, was observed. A significant increase in LVEF at rest at 3 and 6 months after ESWT (from 32.2±6.0 to 34.8±9.6 and 37.7±9.5, P=.03, respectively) was noted. Summed rest score (from 23.9±8.1 to 21.4±7.1, P=.03) and stress score improvement (from 28.2±8.4 to 24.6±6.4, P=.04) by single photon emission computed tomography was registered. Significant clinical improvement accompanied by beneficial changes of LVEF and rest/stress perfusion was found after ESWT. Introduction: With improvement in cardiovascular care, there is a rapidly growing group of patients who remain severely disabled by symptoms of myocardial ischaemia but yet not amenable to conventional revascularization therapy. ESMR is a shockwave therapy given to the area of ischaemic myocardium which theoretically induces angiogenesis and hence improvement in myocardial perfusion and clinical symptoms. Objectives: To analyse the effect of ESMR in patients with refractory angina in improving angina symptoms and myocardial perfusion. Methods: Sixteen patients (81% with three vessels disease and 19% with two vessels disease) who fulfill these inclusion criteria: 1. Patient with refractory angina 2. Presence of angina which cannot be controlled by medical therapy, percutaneous coronary intervention or coronary artery bypass graft surgery 3. Patients with Canadian Cardiovascular Society angina class II to IV 4. Proven reversible myocardial ischaemia as shown by SPECT 5. Patient was declined PCI or CABG by the attending cardiologist or surgeon were recruited and treated with ESMR 3 sessions per week for 3 cycles at intervals of three weeks. Each patient had total of nine sessions with 500 shocks in each session. They were assessed clinically using CCS angina class, Seattle Angina Questionnaire , exercise tolerance test and myocardial perfusion. Results: There were significant improvement in CCS angina class (p-value = 0.001), angina symptoms based on SAQ (p-value = 0.023) and decreased in nitroglycerin usage (p-value = 0.024). An increased in the duration of exercise stress test was demonstrated (7.47 vs 9.85 minutes, p-value < 0.0001) and correlated with an improvement in METS (4.88 vs 6.12, p-value < 0.0001). There was also improvement in mean defect extent score at stress on SPECT, pre and 3 months post ESMR treatment, 29.36 ± 9.75% and 24.63 ± 11.26% (p-value = 0.021) respectively. Conclusion: We observed an overall improvement in both clinical symptoms and myocardial perfusion after ESMR therapy. This exciting novel therapy offers new hope in symptomatic CAD patients not amenable to conventional therapy. 
Congestive Heart Failure

Methods:
We treated 15 patients with severe symptomatic CAD, rejected by the PCI and/or CABG treatments, mean age (71±5,6), 3 female (20%) and 12 male (80%) by ESMR (3 times a week at intervals of four weeks for a total of 3 months, nine treatments patient in total). Before this treatment we have carefully localized ischemic or hibernating segments responsible for the symptoms of patients. After six months of treatment we have carefully analyzed the segmental perfusion by myocardial scintigraphy (SPECT) and segmental and global systolic function by echo. The perfusion was assessed by SPECT, analyzing the global perfusion at rest (SSS; summed stress score;) and stress (SRS; summed rest score;) before and after treatment. At 1,3,6,12 months after we evaluated the presence of angina (CCS class) and the use of nitroglycerin (NP).
Results:
The ESMR therapy has led to an improvement of symptoms to Canadian Cardiovascular Society (CCS), average from 2.8 to 1.27 at 12 months, P<0.0001) and reduced the use of nitroglycerin and hospitalization (p<0.001). Number of of akinetic segments was reduced from 11.5% to 6% (p=0.03). The perfusion evaluated by SPECT has improved statistically significant: SRS average was reduced from 14.4 to 6.55 (p=0.0045), while SSS was reduced from 21.1 to 12 (p=0.006). None patients had any damage or discomfort.
Conclusions:
Our data, even if preliminary and limited, document a definite improvement in term of perfusion, function and clinical benefit, in a very difficult subset of patients. Objectives: An optimal treatment for patients with diffuse obstructive arterial disease unsuitable for catheter-based or surgical intervention is still pending. This study tested the hypothesis that extracorporeal shock wave (ECSW) therapy may be a therapeutic alternative under such clinical situation.
SRS-SSS before and after treatment
Methods:
Myocardial ischemia was induced in male mini-pigs through applying an ameroid constrictor over mid-left anterior descending artery (LAD). Twelve mini-pigs were equally randomized into group 1 (Constrictor over LAD only) and group 2 [Constrictor over LAD plus ECSW (800 impulses at 0.09 mJ/mm 2 ) once 3 months after the procedure].
Results:
The parameters measured by echocardiography did not differ between two groups on days 0 and 90. However, echocardiography and left ventricular (LV) angiography showed higher LV ejection fraction and lower LV end-systolic dimension and volume in group 2 on day 180 (p<0.035). Besides, mRNA and protein expressions of CXCR4 and SDF-1α were increased in group 2 (p<0.04). Immunofluorescence staining also showed higher number of vWF-, CD31-, SDF-1α, and CXCR4-positive cells in group 2 (all p<0.04). Moreover, immunohistochemical staining showed notably higher vessel density but lower mean fibrosis area, number of CD40-positive cells and apoptotic nuclei in group 2 (all p<0.045). Mitochondrial protein expression of oxidative stress was lower, whereas cytochrome-C was higher in group 2 (all p<0.03). Furthermore, mRNA expressions of MMP-9, Bax and caspase-3 were lower, whereas Bcl-2, eNOS, VEGF and PGC-1α were higher in group 2 (all p<0.01).
Conclusion:
ECSW therapy effectively reversed ischemia-elicited LV dysfunction and remodeling through enhancing angiogenesis and attenuating inflammation and oxidative stress. Introduction: To test the effectiveness and feasibility of extracorporeal cardiac shockwave(SW) therapy in patients(pts) with severe coronary artery disease (CAD) unsuitable for revascularization.
Methods:
Extracorporeal SW is performed with the application of 100 shocks/spot at 0.09mJ/mm2 energy flux density for 3-6 spots each time, with three times per week at each series for three series at 1, 5, 9 weeks. The location and depth of SW application are based on thallium scan findings guided by echocardiography. The following parameters will be evaluated including symptoms of angina and needs of nitroglycerine use. The exercise tolerance and dipyridamole thallium 201 myocardial perfusion scan and echocardiography will be followed up after 6 months of initial therapy.
Results: This study included 27 pts, 18 males and 9 females with mean age of 70 + 9 (50-89) yrs old. 14 pts had DM, 7 had CVA, 7 had previous CABG, 15 had old MI. 25 pts had triple vessel disease and 2 had two vessel disease. Each patient received 1200 to 5200 shocks (3881 + 935) respectively during the whole course of therapy. One patient did not complete the study due to recurrent CVA. Among the remaining 26 pts, 11 pts could perform treadmill exercise test, the maximal exercise duration increased from 248 to 319 second (P=0.007). 21 of 26 (80%) pts showed improvement of reversible ischemia by follow up thallium scan. Two patients received coronary angiography and coronary artery showed new neovascularization after SW therapy.
Discussion: Extracorporeal cardiac SW therapy can ameliorate myocardial ischemia detected by thallium 201 myocardial perfusion scan and improve symptoms of angina.
